Akari醫療公共 AKTX 深 滬
等待開盤 12-12 09:30:00 美东时间
0.41
+0.030
+7.87%
華盛通- 最 高0.425
- 今 開0.393
- 成交量 36.26万股
- 最 低 0.3506
- 昨 收 0.3801
- 總市值 1465.33万
- 52周最高 1.73
- 市盈率 靜 --
- 換手率 1.01%
- 52周最低 0.2649
- 委 比 -22.13%
- 總股本 3573.97万
- 歷史最高 2380.00
- 量 比 0.24
- 振 幅 19.57%
- 歷史最低 0.2649
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Akari Therapeutics, a biotech company, announced the publication of a new CEO Corner segment highlighting its progress in developing an innovative ADC platform targeting the spliceosome. The company's PH1 payload, designed to disrupt RNA splicing, shows potential as a monotherapy or in combination with checkpoint inhibitors. Its lead candidate, AKTX-101, targeting the Trop2 receptor, is advancing toward clinical trials in Q4 2026. Akari aims to a...
12-04 14:00
Akari Therapeutics Announces Release of the Next CEO Corner Segment
Akari Therapeutics announced the publication of its latest CEO Corner segment, where CEO Abizer Gaslightwala highlights the company's innovation in antibody drug conjugates (ADCs), particularly its novel PH1 payload with a dual mechanism of action. He also discusses Akari's next-generation ADC discovery platform and its mission to develop differentiated therapies for patients. The PH1 payload, a spliceosome modulator, disrupts RNA splicing in can...
11-25 14:00
Akari Therapeutics appoints interim CFO
Akari Therapeutics (AKTX) announced the appointment of Kameel D. Farag as its interim chief financial officer, who joined Akari last month. Farag most recently served as CFO and head of business oper...
11-18 21:52
Akari Therapeutics Appoints Kameel D. Farag As Interim Chief Financial Officer
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the appointment of Kameel D. Farag as its Interim Chief Financial
11-18 21:41
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Teradata Corp (NYSE:TDC) rose sharply in pre-market trading after the...
11-05 18:09
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
Akari Therapeutics announced the formation of its Scientific Advisory Board (SAB) with Dr. Sara Hurvitz as its inaugural member. Dr. Hurvitz, an internationally recognized oncology expert, specializes in ADCs and targeted therapies for breast cancer. She brings extensive clinical expertise in managing cancers across all stages, particularly in neoadjuvant treatments and immune-based approaches. Akari is developing next-generation spliceosome payl...
10-30 12:35
Akari Therapeutics Appoints Kameel Farag as Interim CFO
The latest announcement is out from Akari Therapeutics ( ($AKTX) ). On October ...
10-24 05:21
Akari Therapeutics Announces Launch of CEO Corner Platform
Akari Therapeutics launched its CEO Corner platform, featuring President and CEO Abizer Gaslightwala, to provide deeper insights into company developments and pipeline progress. The platform aims to offer stakeholders additional perspectives beyond press releases, fostering clearer communication about the company's vision and goals. Akari focuses on developing innovative ADCs, with its lead candidate AKTX-101 targeting Trop2 receptors and deliver...
10-22 13:05
Akari Therapeutics Announces A $2.5M Registered Direct Offering Of 3,125,000 American Depositary Shares At $0.80 Per ADS
Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the
10-15 20:37
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
Akari Therapeutics announced that its abstract on a novel splicing-targeted ADC payload has been accepted for oral presentation at the 40th Annual SITC Meeting in November 2025. The payload, PH1, modulates RNA splicing in cancer cells, inducing cell death and immune activation, with potential synergy with checkpoint inhibitors. Akari's lead candidate, AKTX-101, has shown significant activity and prolonged survival in preclinical studies. The pres...
10-03 13:30
